Several adenosine or cytidine deaminase enzymes deaminate transcript sequences in a cell type or environment-dependent manner by a programmed process called RNA editing. RNA editing enzymes catalyze A>I or C>U transcript alterations and have the potential to change protein coding sequences. In this brief review, we highlight some recent work which shows aberrant patterns of RNA editing in cancer. Transcriptome sequencing studies reveal increased or decreased global RNA editing levels depending on the tumor type. Altered RNA editing in cancer cells may provide a selective advantage for tumor growth and resistance to apoptosis. RNA editing may promote cancer by dynamically recoding oncogenic genes, regulating oncogenic gene expression by noncoding RNA and miRNA editing, or by transcriptome scale changes in RNA editing levels which may affect innate immune signaling. Although RNA editing markedly increases complexity of the cancer cell transcriptomes, cancer-specific recoding RNA editing events have yet to be discovered. Epitranscriptomic changes by RNA editing in cancer represent a novel mechanism contributing to sequence diversity independently of DNA mutations. Therefore, RNA editing studies should complement genome sequence data to understand the full impact of nucleic acid sequence alterations in cancer.
Introduction
The central dogma of biology refers to the faithful transmission of genetic information from DNA to RNA and from RNA to protein. This dogma underlies the rationale to examine the genome to understand pathogenesis of human diseases especially cancer.
Abundant data now show that DNA mutations are fundamental to cancer initiation and progression (1) . Whereas genetic linkage based approaches in rare cancer-prone families have identified many classical tumor suppressor genes, recent high throughput sequence analyses of cancer genomes showed somatic mutations driving the neoplastic process (2) .
Recent studies also show that enzymatic alterations in RNA sequences, without any corresponding mutation at the DNA level, can also contribute to pathogenesis of cancer (3) (4) (5) (6) (7) .
RNA editing refers to programmed alterations in transcripts catalyzed by adenosine or cytidine deaminating enzymes, and benefits the organism by allowing cell-type specific, developmentally-regulated or environmentally-induced expression of protein isoforms (8, 9) . RNA editing alters adenine to inosine (A>I) and cytosine to uracil (C>U) by adenosine and cytidine deaminases, respectively. These base transitions at the transcript level can lead to missense (by A>I and C>U editing) or nonsense (by C>U editing) protein alterations. Recent sequencing studies highlight that cancer cell transcriptomes are more complex than their genomes in part due to widespread RNA editing (4) (5) (6) (7) . Since levels of RNA editing may dynamically change by micro-environmental factors or during tumor progression, and that edited transcripts have a limited life span, the functional impact of RNA editing on cancer cells will be different than those of permanent DNA mutations. Here, we provide a brief overview of the known RNA editing enzymes and highlight some recent studies on the role of RNA editing in cancer.
RNA editing by ADARs
A>I RNA editing is catalyzed by the ubiquitously expressed ADAR (ADAR1) and ADARB1 (ADAR2) adenosine deaminase enzymes (Table 1) (8) . ADARB2 (ADAR3) enzyme is considered catalytically inactive. Full length ADAR1p150 and amino terminal 4 truncated ADAR1p110 isoforms of ADAR are transcribed by alternative promoter usage.
Except for ADARp150, an interferon-inducible isoform which can accumulate in the cytoplasm, all other ADARs are localized to the nucleus. ADARs catalyze site-specific RNA editing in short imperfect RNA duplexes, whereas hyperediting that involves many adenosines occurs in long perfect RNA duplexes. Majority of ADAR-mediated RNA editing events in long duplex RNAs occurs in the 3'-UTR and 5'-UTR of mRNAs and in introns, especially in the context of Alu sequences. Noncoding edited sites may play roles in the regulation of splicing, gene expression and miRNA binding (10) . In addition, RNA editing by ADAR recodes mRNAs of several genes including NEIL1 (11), BLCAP, FLNA (12) and NARF (13) .
Site-specific A>I RNA editing events that alter the amino acid code by missense substitutions occurs only in a handful of genes, which are often involved in neurotransmission in brain. For example, ADARB1 edits GluR-B mRNA leading to near 100% change from the germ line encoded glutamine at amino acid 607 to arginine at the mRNA level. This change significantly alters the AMPA receptor neurotransmitter function. Loss of this editing in Adarb1-/-mice leads to lethal seizures shortly after birth (14) . In contrast, loss of Adar gene leads to early embryonic lethality via defective hematopoietic stem cells, increased activation of interferon signaling and apoptosis (15) , although the identity of the edited RNAs involved is unknown.
Recently germ line mutations in ADAR were identified in the autoimmune disorder Aicardi-Goutières syndrome (AGS) (16) . ADAR mutations in AGS and Adar-/-mice upregulate interferon type I (IFN1) regulated genes. AGS is a genetically heterogeneous Mendelian disease caused by mutations in several genes involved in nucleic acid metabolism and is characterized by early onset progressive brain disease, certain skin lesions, glaucoma and, in some cases, features resembling systemic lupus erythematosus (17) . Upregulation of IFN1 signaling pathway by ADAR mutations suggests that the editing activity of ADAR is required to block activation of innate immune signaling. It is thought that the lack of ADAR-mediated RNA editing in double stranded RNAs 5 stimulates cytosolic RNA sensing by MDA5-MAVS pathways, which are normally blocked by mismatched I-U base pairs (18, 19) .
RNA editing by APOBECs
C>U RNA editing catalyzed by the APOBEC cytidine deaminases is significantly less common than A>I editing in baseline transcriptome sequencing studies. The prototype of cytidine deaminases that edit RNA is the APOBEC1 enzyme. APOBEC1 site-specifically edits mRNA of the APOB gene to introduce a premature stop codon enabling intestinal cells to produce a short protein isoform of Apo B (20) . Recent transcriptome sequencing studies identified additional RNA editing sites of APOBEC1, mostly in the 3'-UTRs (21, 22) . APOBEC1 was the only C>U RNA editing enzyme known until the discovery of APOBEC3A (A3A) (23) . A3A differs from other RNA editing enzymes in that its editing function is observed only after induction by certain stimulations in monocytes and macrophages or by exogenous overexpression in 293T cells (24) . Hypoxia (1% O2) or IFN1 in primary peripheral blood monocytes or IFN1 in monocyte-derived macrophages induce widespread site-specific RNA editing by A3A. In monocytes, hypoxia and IFN1 additively increases RNA editing levels which leads to recoding of over 80% of transcripts of certain genes. In contrast to ADARs, most RNA editing by A3A is highly site-specific and targets the coding regions of genes, often resulting in missense/nonsense alterations.
Whether other APOBECs, including APOBEC2, A3B, A3C, A3DE, A3F, A3G, A3H and 
Altered RNA editing in cancer
Recoding RNA editing in cancer RNA editing has been linked to tumorigenesis by either site-specific editing of tumor promoting genes or by transcriptome-scale changes in RNA editing levels.
A>I RNA editing of AZIN1, which encodes an antizyme inhibitor, causes S367G amino acid substitution. RNA editing level of AZIN1 increases by at least 10% in hepatocellular carcinoma compared to normal unaffected liver (3). This editing generates an isoform with increased affinity to antizyme, promoting cell proliferation by reducing antizymemediated degradation of ornithine decarboxylase and cyclin D1. Site-specific A>I RNA editing of transcription factor PROX1 causes several missense alterations including E328G, R334G and H536R in a small number of esophageal, pancreatic and colon cancer samples, but no such editing is seen in a number of cDNA libraries of many normal tissues (32) . By comparing the genome/transcriptome sequences, recoding A>I RNA editing, causing N136S amino acid change in RHOQ is found in colorectal cancer (33) .
This editing increases RhoQ GTPase enzyme activity, cancer invasion potential and recurrence of colorectal cancer when present in the tumor. Increased recoding (M2269V) RNA editing of filamin B gene (FLNB) is noted in hepatocellular (34) and esophageal squamous cell carcinomas (35) . Increased recoding RNA editing of DNA repair enzyme NEIL1 (K242R) is identified in non-small-cell lung cancer samples as a result of ADAR gene amplification (36) . A rare example of C>U RNA editing in cancer involves the neurofibromatosis type I gene (NF1) mRNA editing that introduces a nonsense mutation in subset of peripheral nerve-sheath tumors (37) (38) (39) .
Reduced recoding RNA editing has also been observed in several tumors. For instance, RNA editing of GluR-B also causes R701G substitution in normal cerebellum and skin but it is markedly reduced in medulloblastoma cell lines and basal cell carcinoma samples (40) . GluR-B Q607R editing is substantially lower in malignant gliomas which have reduced expression of the ADARB1 enzyme (41) . In gastric cancer, oncogenic activity is promoted by the loss of ADARB1 which normally mediates recoding RNA editing H241R in PODXL to eliminate tumor promoting function of the wild type gene (42) . Chen et al (43) suggested that RNA editing enables proapoptotic function of IGFBP7, the loss of which may promote tumorigenesis in esophageal squamous cell carcinoma. The chloride receptor Gabra3 transcripts undergo recoding editing in the brain (44) . Reduced RNA editing of GABRA3 in breast cancer is suggested to promote tumor progression, invasion and metastatic potential (45) .
Noncoding RNA editing in cancer
Noncoding RNA editing is also suggested to promote tumorigenesis. In CD34+/CD117+ myeloblasts of acute myeloid leukemia, transcripts of PTPN6, which encodes SH2 domain-containing tyrosine phosphatase, were found to retain an intron as a result of multiple A>I RNA editing events mainly at the intronic putative branch site (46) Paz-Yaacov (5) showed increased A>I RNA editing levels (>5%) in most cancer types, largely at Alu sites, but also at 60 recoding sites. Lower editing levels correlated with a better survival in hepatocellular and head/neck carcinoma cases. Authors suggested that mutation load contributed by RNA editing may be more than those contributed by DNA mutations. Fumagalli et al (6) showed that the same sites are edited in primary breast cancer, normal breast tissue and breast cancer cell lines. However, higher frequency of editing is observed in tumor tissues as compared to normal and correlates positively with higher ADAR expression. Editing was mostly confined to Alu sites.
Zhang et al (7) showed widespread A>I RNA editing events in cancer but they were not specific to a certain cancer type and were present in all tissues including normal controls. They identified 166 differentially edited genes between normal and tumor tissues.
Smallest number (n=11) of differentially edited genes occurred in esophageal carcinoma, largest (n=62) in breast adenocarcinoma. They confirmed increased editing levels of AZIN1 and decreased levels in IGFBP7 in most tumor types. The authors did not find a strong correlation between editing levels and ADAR expression levels, and suggested that RNA editing of 3'-UTR miRNA binding sites may strongly influence expression levels of tumor promoting or suppressor genes.
Transcriptome sequencing studies in different cancer types are summarized in Supplementary Table 1 . Although ADAR is the primary mediator of the A-to-I RNA editing events, there is no strong consensus on how to explain the editing efficacy of the events by correlation analysis against ADAR expression profiles. RNA editing efficacy is generally defined by the frequency of editing events or the extent of editing. Several studies reported that frequency of editing events is correlated with ADAR expression levels (4), however, others also show that editing levels might not be directly associated with the ADAR expression profiles (7) . This might suggest an alternative editing mediator (e.g. ADARB1) is activated to regulate the editing mechanism. In general, majority of the events have low editing levels and consequently it is often difficult to make a confident estimation when the sequencing depth is low. Increasing the sequencing depth might contribute to identifying the true positive hits and could improve the correlation of editing levels and ADAR expression profiles or better able to address the inconsistencies reported in the literature. We obtained reported gene expression profiles based on RNA-sequencing for the cancer types with at least five normal samples, from The Cancer Genome Atlas (TCGA) project (https://portal.gdc.cancer.gov/).
Comparing the distribution of expression levels for ADAR and ADARB1 between the tumor and normal samples for the selected cancers, fold change in their median expression levels and corresponding significance was calculated using Mann-Whitney U test (See Supplementary Table 1, Figure 1 ). Figure 1 
Summary and outlook
Initial studies of RNA editing in cancer suggests that both genome and transcriptome sequencing studies are required to capture all sources of protein mutations in cancer.
Several patterns emerge from these initial studies. (a) Although RNA editing levels are altered in cancer, RNA editing does not appear to create new cancer-specific alterations since all sites edited in cancer are also edited in normal control tissues to some degree.
Thus, cancer related changes in RNA editing appear to be in quantity rather than quality. 
